A Phase 2/3 interventional study of Rilogrotug in Cachexia; Cancer, Cachexia and Cachexia-Anorexia Syndrome, sponsored by AVEO Pharmaceuticals, Inc.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by AVEO Pharmaceuticals, Inc. (part of LG Chem) · Phase 2/3, Interventional, and Treatment
The purpose of the OLE study is to evaluate the long-term safety and tolerability of rilogrotug treatment in participants who have completed the parent study and are eligible to receive continued treatment.
This multicenter, OLE study is designed to allow participants who have completed the parent study to continue receiving rilogrotug for up to an additional 6 months. The parent study is for treatment of weight loss and anorexia in participants with cachexia who have also been diagnosed with mCRC or mNSCLC and are receiving first line anticancer standard of care.
336 studies on the registry are indexed under Cachexia; 76 are open to participants now.
This study's planned enrollment of 400 is above the median of 66 across 226 interventional studies indexed under Cachexia.
Browse Cachexia studies →AVEO Pharmaceuticals, Inc. is the lead sponsor of 35 studies on the registry; 3 are open to participants now.
First submitted after AVEO Pharmaceuticals, Inc. became part of LG Chem.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
intravenous (IV) administration
Biological: Rilogrotug
IV administration
Biological: Rilogrotug
Rilogrotug (AV-380) is a humanized immunoglobulin G1 kappa monoclonal antibody that binds to growth differentiation factor-15 (GDF-15).
To evaluate the safety and tolerability of long-term rilogrotug administration
Adverse events and Laboratory abnormalities
Time frame: 26 weeks
To evaluate the long-term effect of rilogrotug on body weight
Change and percent change from baseline in body weight
Time frame: From enrollment to 26 weeks
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rilogrotug